CSI-Dx®: AN UNTARGETED TEST, FOR TARGETED TREATMENT DECISIONS
Some disease states present unique challenges in regards to accurate pathogen identification and subsequent targeted, effective treatment. Alternative diagnostic assays can often yield inaccurate or confusing results.
CSI-Dx™ removes the clinical guesswork by providing solid evidence of active microbial infections and co-infections through the identification of expressed pathogenic RNA. CSI-Dx™ can simultaneously detect all active pathogens in a single sample, with a database that comprises over 25000 curated pathogenic genomes. Sequencing of nucleic acids directly from clinical samples has allowed for the detection of a wide array of pathogens and circumvents many of the limitations seen in other methods of diagnostics, such as culture or PCR. The CSI-Dx™ test has been analytically validated to report the presence of pathogenic microbial nucleic acid when present at levels above each microbe’s established Limit of Detection (LOD), as low as 3 cells per mL of specimen.
How It Works
Patient provides a sample which is delivered to the lab.
Wet Lab Processing
The sample undergoes CSI’s proprietary RNA extraction and sequencing preparation which targets only the active pathogens present in a sample.
After returning the RNA code to a stable cDNA equivalent through reverse transcription, the prepared sample is sequenced and data is streamed directly into CSI’s secure computational infrastructure.
RAPID-Dx® Bioinformatic Analysis
All data is analyzed and filtered through via CSI’s proprietary bioinformatic pipeline RAPID-Dx®.
Post analysis, a clinical report consisting of all pathogens detected above threshold can be automatically sent to the ordering physician via CSI’s customized Laboratory Information Management System (LIMS). The report details the presence of any detected microbes giving physicians actionable data for diagnosis and treatment decisions.